KEYMED BIOSCIENCES -0001 (F:64Z) — Stock Price
KEYMED BIOSCIENCES -0001 (F:64Z) is currently trading at €9.00 EUR, up 2.27% today. Over the past 52 weeks, shares have ranged between €4.94 and €9.55. This page tracks KEYMED BIOSCIENCES -0001's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see 64Z market cap overview.
KEYMED BIOSCIENCES -0001 (64Z) Stock Price Chart — Daily History & Trading Volume
The chart below tracks KEYMED BIOSCIENCES -0001's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
KEYMED BIOSCIENCES -0001 Income Statement — Revenue, Profit & Earnings by Year
KEYMED BIOSCIENCES -0001's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | €716.31 Million | €428.12 Million | €354.10 Million | €100.06 Million | €110.27 Million |
| Cost of Revenue | €88.05 Million | €12.20 Million | €36.88 Million | €2.58 Million | €17.20 Million |
| Gross Profit | €628.26 Million | €415.92 Million | €317.22 Million | €97.48 Million | €93.07 Million |
| Research & Development | €723.53 Million | €735.19 Million | €596.28 Million | €507.37 Million | €358.16 Million |
| SG&A | €504.20 Million | €298.83 Million | €177.01 Million | €133.91 Million | €92.45 Million |
| Total Operating Expenses | €1.26 Billion | €1.01 Billion | €788.89 Million | €578.33 Million | €481.59 Million |
| Operating Income | €-547.69 Million | €-586.16 Million | €-434.80 Million | €-478.26 Million | €-371.32 Million |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | — | — |
| Interest Expense | €16.91 Million | €18.46 Million | €17.26 Million | €8.22 Million | €11.13 Million |
| Income Before Tax | €-520.72 Million | €-508.65 Million | €-356.19 Million | €-303.60 Million | €-3.89 Billion |
| Income Tax Expense | — | — | — | — | — |
| Net Income | €-522.64 Million | €-515.24 Million | €-359.36 Million | €-308.12 Million | €-3.89 Billion |
KEYMED BIOSCIENCES -0001 Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes KEYMED BIOSCIENCES -0001's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | €4.22 Billion | €3.77 Billion | €3.88 Billion | €3.93 Billion | €3.93 Billion |
| Total Current Assets | €2.42 Billion | €2.47 Billion | €2.94 Billion | €3.31 Billion | €3.58 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | €1.42 Billion | €1.74 Billion | €1.87 Billion | €2.57 Billion | €2.00 Billion |
| Net Receivables | €100.85 Million | €62.85 Million | €16.09 Million | €0.00 | — |
| Inventory | €195.98 Million | €111.42 Million | €56.35 Million | €44.49 Million | €16.39 Million |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | €1.44 Billion | €1.29 Billion | €896.11 Million | €593.10 Million | €289.07 Million |
| Total Current Liabilities | €836.29 Million | €747.73 Million | €314.18 Million | €379.70 Million | €112.08 Million |
| Long-term Debt | €258.03 Million | €257.19 Million | €331.83 Million | €28.80 Million | €0.00 |
| Net Debt | €264.05 Million | €311.15 Million | — | — | — |
| Total Stockholder Equity | €2.77 Billion | €2.47 Billion | €2.99 Billion | €3.34 Billion | €3.65 Billion |
| Retained Earnings | €-6.69 Billion | €-6.16 Billion | €-5.65 Billion | €-5.29 Billion | €3.65 Billion |
KEYMED BIOSCIENCES -0001 Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how KEYMED BIOSCIENCES -0001 generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | €-712.41 Million | €-789.63 Million | €-303.62 Million | €-401.93 Million | €-214.64 Million |
| Capital Expenditures | €336.48 Million | €214.50 Million | €382.61 Million | €279.55 Million | €172.86 Million |
| Free Cash Flow | €-1.05 Billion | €-1.00 Billion | €-686.23 Million | €-681.48 Million | €-387.50 Million |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | €27.76 Million | €34.35 Million | €40.08 Million | €48.57 Million | €116.82 Million |
| Depreciation | €98.03 Million | €93.23 Million | €69.16 Million | €36.12 Million | €21.02 Million |
| Change in Cash | €115.39 Million | €-438.03 Million | €236.71 Million | €-1.06 Billion | €1.39 Billion |
KEYMED BIOSCIENCES -0001 Earnings History — EPS Actual vs. Analyst Estimates
Track KEYMED BIOSCIENCES -0001's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
Earnings history is not currently available for KEYMED BIOSCIENCES -0001.